-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-517458-90-00
5
2025-06-06
Chronic obstructive pulmonary disease (COPD)
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-514531-18-00
3
2025-05-20
Acute Myeloid Leukemias
-
2024-514953-31-00
4
2025-05-20
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2024-515984-68-00
4
2025-05-20
Non-small cell lung cancer (NSCLC)
-
2024-517921-14-00
9
2025-05-07
Neuroendocrine tumors of midgut origin
-
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2023-506856-25-00
4
2025-03-12
Corneal ulcer
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-512960-75-00
5
2025-02-04
Resectable Non-small cell lung cancer
-
2023-503675-24-00
5
2025-01-17
Triple-negative Breast Cancer
-
2023-509883-89-00
5
2025-01-09
Epidermal growth factor receptor (EGFR) mutation-positive, locally adv
-
2024-512798-29-00
5
2025-01-07
Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreat
-
2024-511497-79-00
4
2024-12-30
Hormone receptor positive (HR+), human epidermal growth factor recepto
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-515381-14-00
6
2024-11-20
heartburn and or reflux
-
2024-516595-15-00
9
2024-11-11
Hidradenitis suppurativa